NASDAQ:AKBA Akebia Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.40 -0.01 (-2.41%) (As of 07/6/2022 09:35 AM ET) Add Compare Share Today's Range$0.39▼$0.4050-Day Range$0.32▼$0.4552-Week Range$0.30▼$3.71Volume5,145 shsAverage Volume17.31 million shsMarket Capitalization$73.43 millionP/E RatioN/ADividend YieldN/APrice Target$1.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Akebia Therapeutics MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside327.9% Upside$1.75 Price TargetShort InterestHealthy8.53% of Shares Sold ShortDividend StrengthN/ASustainability-1.75Upright™ Environmental ScoreNews Sentiment0.50Based on 5 Articles This WeekInsider TradingSelling Shares$1,644 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.88) to ($0.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.15 out of 5 starsMedical Sector326th out of 1,426 stocksPharmaceutical Preparations Industry153rd out of 682 stocks 3.0 Analyst's Opinion Consensus RatingAkebia Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.75, Akebia Therapeutics has a forecasted upside of 327.9% from its current price of $0.41.Amount of Analyst CoverageAkebia Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted8.53% of the outstanding shares of Akebia Therapeutics have been sold short.Short Interest Ratio / Days to CoverAkebia Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Akebia Therapeutics has recently decreased by 11.92%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAkebia Therapeutics does not currently pay a dividend.Dividend GrowthAkebia Therapeutics does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAkebia Therapeutics has received a 57.94% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Various other types of medication (V)" products. See details.Environmental SustainabilityThe Environmental Impact score for Akebia Therapeutics is -1.75. Previous Next 2.5 News and Social Media Coverage News SentimentAkebia Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Akebia Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 21 people have searched for AKBA on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.MarketBeat Follows9 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akebia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,644.00 in company stock.Percentage Held by InsidersOnly 2.92% of the stock of Akebia Therapeutics is held by insiders.Percentage Held by Institutions55.34% of the stock of Akebia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.88) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akebia Therapeutics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akebia Therapeutics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkebia Therapeutics has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AKBA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About Akebia Therapeutics (NASDAQ:AKBA) StockAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More AKBA Stock News HeadlinesJuly 3, 2022 | marketwatch.comThinking about buying stock in Akebia Therapeutics, Agile Therapeutics, Mullen Automotive, Evofem Biosciences, or Endo International?July 3, 2022 | americanbankingnews.comAkebia Therapeutics (NASDAQ:AKBA) Now Covered by Analysts at StockNews.comJune 30, 2022 | seekingalpha.comAkebia regains rights to kidney disease therapy after termination of deals with OtsukaJune 30, 2022 | finance.yahoo.comAkebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with OtsukaJune 25, 2022 | americanbankingnews.comAkebia Therapeutics (NASDAQ:AKBA) Research Coverage Started at StockNews.comJune 17, 2022 | americanbankingnews.comAkebia Therapeutics (NASDAQ:AKBA) Coverage Initiated by Analysts at StockNews.comJune 15, 2022 | americanbankingnews.comHead to Head Survey: Nurix Therapeutics (NASDAQ:NRIX) & Akebia Therapeutics (NASDAQ:AKBA)June 14, 2022 | americanbankingnews.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Recommendation of "Hold" by AnalystsJune 3, 2022 | finance.yahoo.comAkebia Therapeutics to Present at Jefferies Healthcare ConferenceMay 19, 2022 | finance.yahoo.comAkebia Therapeutics to Present at H.C. Wainwright Global Investment ConferenceMay 16, 2022 | seekingalpha.comAkebia falls as agreement with Otsuka Pharma endsMay 16, 2022 | markets.businessinsider.comExpert Ratings for Akebia TherapeuticsMay 9, 2022 | seekingalpha.comAkebia Therapeutics, Inc. (AKBA) CEO John Butler on Q1 2022 Results - Earnings Call TranscriptMay 5, 2022 | finance.yahoo.comZoetis (ZTS) Tops Q1 Earnings and Revenue EstimatesMay 2, 2022 | finance.yahoo.comAkebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?May 2, 2022 | finance.yahoo.comAkebia Therapeutics to Report First Quarter Financial ResultsApril 28, 2022 | benzinga.comCLASS ACTION UPDATE for AI, AKBA and SDIG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of ShareholdersApril 27, 2022 | baystreet.caThe Gross Law Firm Announces Class Actions on Behalf of Shareholders of AKBA, AUPH and BKKTApril 7, 2022 | finance.yahoo.comSee Why Does HC Wainwright Maintain Neutral On Akebia StockApril 7, 2022 | finance.yahoo.comFollowing FDA rejection, Akebia lays off 180 workersApril 6, 2022 | finance.yahoo.comAkebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2022April 1, 2022 | finance.yahoo.comAkebia: Is There Any Value Left After the CRL? Analyst Weighs InMarch 31, 2022 | seekingalpha.comAkebia extends slide as Wall Street reacts to FDA rejection of kidney disease drugMarch 31, 2022 | finance.yahoo.comAkebia stock tumbles after FDA rejects anemia drugMarch 30, 2022 | nasdaq.comU.S. FDA declines to approve Akebia's anemia drug on safety concernsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKBA CUSIPN/A CIK1517022 Webwww.akebia.com Phone(617) 871-2098Fax617-871-2099Employees426Year FoundedN/ACompany Calendar Last Earnings5/09/2022Today7/06/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$1.75 High Stock Price Forecast$2.00 Low Stock Price Forecast$1.25 Forecasted Upside/Downside+337.4%Consensus RatingHold Rating Score (0-4)2 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-282,840,000.00 Net Margins-123.64% Pretax Margin-123.64% Return on Equity-266.13% Return on Assets-48.47% Debt Debt-to-Equity RatioN/A Current Ratio1.19 Quick Ratio1.04 Sales & Book Value Annual Sales$213.58 million Price / Sales0.34 Cash FlowN/A Price / Cash FlowN/A Book Value$0.44 per share Price / Book0.91Miscellaneous Outstanding Shares183,530,000Free Float178,174,000Market Cap$73.43 million OptionableOptionable Beta1.49 Akebia Therapeutics Frequently Asked Questions Should I buy or sell Akebia Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last twelve months. There are currently 6 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Akebia Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AKBA, but not buy additional shares or sell existing shares. View analyst ratings for Akebia Therapeutics or view top-rated stocks. What is Akebia Therapeutics' stock price forecast for 2022? 6 analysts have issued 12-month price targets for Akebia Therapeutics' shares. Their AKBA stock forecasts range from $1.25 to $2.00. On average, they predict Akebia Therapeutics' stock price to reach $1.75 in the next year. This suggests a possible upside of 337.4% from the stock's current price. View analysts' price targets for Akebia Therapeutics or view top-rated stocks among Wall Street analysts. How has Akebia Therapeutics' stock performed in 2022? Akebia Therapeutics' stock was trading at $2.26 at the beginning of the year. Since then, AKBA stock has decreased by 82.3% and is now trading at $0.4001. View the best growth stocks for 2022 here. When is Akebia Therapeutics' next earnings date? Akebia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Akebia Therapeutics. How were Akebia Therapeutics' earnings last quarter? Akebia Therapeutics, Inc. (NASDAQ:AKBA) released its quarterly earnings results on Monday, May, 9th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.27) by $0.08. The biopharmaceutical company had revenue of $61.70 million for the quarter, compared to analyst estimates of $44.37 million. Akebia Therapeutics had a negative net margin of 123.64% and a negative trailing twelve-month return on equity of 266.13%. During the same quarter in the previous year, the company earned ($0.45) earnings per share. View Akebia Therapeutics' earnings history. Who are Akebia Therapeutics' key executives? Akebia Therapeutics' management team includes the following people: Mr. John P. Butler MBA, CEO, Pres & Director (Age 58, Pay $1.36M) (LinkedIn Profile)Mr. David A. Spellman, Sr. VP, CFO & Treasurer (Age 45, Pay $790.54k) (LinkedIn Profile)Mr. Michel Dahan, Sr. VP & COO (Age 43, Pay $795.39k) (LinkedIn Profile)Mr. Dell Faulkingham, Sr. VP & Chief Commercial Officer (Age 49, Pay $797.88k)Dr. Steven Keith Burke, Sr. VP of R&D and Chief Medical Officer (Age 61, Pay $821.54k) (LinkedIn Profile)Ms. Violetta Cotreau, Sr. VP, Chief Accounting Officer & Principal Accounting Officer (Age 49) (LinkedIn Profile)Ms. Nicole R. Hadas, Sr. VP, Chief Legal Officer & Sec. (Age 49)Mercedes Carrasco, Director of Corp. CommunicationsMr. Douglas Jermasek M.B.A., VP of Marketing & StrategyMs. Kristie A. Bolieau, VP & Corp. Controller What is John Butler's approval rating as Akebia Therapeutics' CEO? 28 employees have rated Akebia Therapeutics CEO John Butler on Glassdoor.com. John Butler has an approval rating of 97% among Akebia Therapeutics' employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Akebia Therapeutics' key competitors? Some companies that are related to Akebia Therapeutics include AC Immune (ACIU), Biotech Acquisition (BIOT), CytoDyn (CYDY), Aadi Bioscience (AADI), Alpine Immune Sciences (ALPN), G1 Therapeutics (GTHX), Alaunos Therapeutics (TCRT), LianBio (LIAN), Rallybio (RLYB), Verona Pharma (VRNA), CymaBay Therapeutics (CBAY), Provention Bio (PRVB), PepGen (PEPG), Thorne HealthTech (THRN) and InterCure (INCR). View all of AKBA's competitors. What other stocks do shareholders of Akebia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T). What is Akebia Therapeutics' stock symbol? Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA." How do I buy shares of Akebia Therapeutics? Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Akebia Therapeutics' stock price today? One share of AKBA stock can currently be purchased for approximately $0.40. How much money does Akebia Therapeutics make? Akebia Therapeutics (NASDAQ:AKBA) has a market capitalization of $73.43 million and generates $213.58 million in revenue each year. The biopharmaceutical company earns $-282,840,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. How many employees does Akebia Therapeutics have? Akebia Therapeutics employs 426 workers across the globe. How can I contact Akebia Therapeutics? Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The official website for Akebia Therapeutics is www.akebia.com. The biopharmaceutical company can be reached via phone at (617) 871-2098, via email at ir@akebia.com, or via fax at 617-871-2099. This page (NASDAQ:AKBA) was last updated on 7/6/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
